文献速递心外重症与机械循环支持

免疫功能受损患者接受ECMO支持治疗严重急性呼吸衰竭的临床结局

Clinical outcomes of immunocompromised patients on extracorporeal membrane oxygenation support for severe acute respiratory failure.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该多中心回顾性研究纳入韩国16家医院461例因严重急性呼吸衰竭接受ECMO支持的成人患者,其中118例(25.6%)免疫功能受损。免疫功能受损患者ECMO成功脱机率更低(46.6% vs 58.9%,P=0.021),6个月死亡率更高(74.6% vs 64.7%,校正OR 2.10,95%CI 1.02-4.35,P=0.045)。

要点

  • 免疫功能受损患者ECMO成功脱机率显著低于免疫功能正常患者。
  • 免疫功能受损与6个月死亡率升高独立相关(校正OR 2.10)。
  • 免疫功能受损患者住院死亡率有升高趋势但未达统计学显著。

核心结论

  • 免疫功能受损患者因严重急性呼吸衰竭接受ECMO支持时,短期和长期预后均差于免疫功能正常患者。

研究设计与样本

  • 2012年1月至2015年12月韩国16家三级或大学附属医院的回顾性多中心队列研究,纳入461例因严重急性呼吸衰竭接受ECMO支持的连续成人患者,按ECMO启动时免疫功能状态分为两组。

主要发现

  • 461例患者中118例(25.6%)免疫功能受损。
  • 免疫功能受损患者较免疫功能正常患者更年轻,血红蛋白和血小板计数更低。
  • 两组通气血流参数及辅助/挽救治疗使用相似,但俯卧位通气在免疫功能正常患者中更常用。
  • 免疫功能受损患者ECMO成功脱机率更低(46.6% vs 58.9%;P=0.021)。
  • 免疫功能受损患者住院死亡率更高(66.1% vs 59.8%;P=0.22),6个月死亡率更高(74.6% vs 64.7%,校正OR 2.10,95%CI 1.02-4.35;P=0.045)。

临床怎么用

  • 对免疫功能受损的严重急性呼吸衰竭患者启动ECMO前,应充分告知其脱机成功率更低及6个月死亡率更高的风险。

局限性

  • 回顾性研究设计可能存在选择偏倚和混杂因素。
  • 免疫功能受损定义及具体病因未在摘要中详述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There are limited data regarding extracorporeal membrane oxygenation (ECMO) support in immunocompromised patients, despite an increase in ECMO use in patients with respiratory failure. The aim of this study was to investigate the clinical characteristics and outcomes of immunocompromised patients requiring ECMO support for severe acute respiratory failure. METHODS: Between January 2012 and December 2015, all consecutive adult patients with severe acute respiratory failure who underwent ECMO for respiratory support at 16 tertiary or university-affiliated hospitals in South Korea were enrolled retrospectively. The patients were divided into 2 groups based on the immunocompromised status at the time of ECMO initiation. In-hospital and 6-month mortalities were compared between the 2 groups. In addition, association of immunocompromised status with 6-month mortality was evaluated with logistic regression analysis. RESULTS: Among 461 patients, 118 (25.6%) were immunocompromised. Immunocompromised patients were younger and had lower haemoglobin and platelet counts than immunocompetent patients. Ventilatory parameters and the use of adjunctive/rescue therapies were similar between the 2 groups, but prone positioning was more commonly used in immunocompetent patients. Successful weaning rates from ECMO (46.6% vs 58.9%; P = 0.021) was lower and hospital mortality (66.1% vs 59.8%; P = 0.22) was higher in immunocompromised patients. In addition, immunocompromised status was associated with higher 6-month mortality (74.6% vs 64.7%, adjusted odds ratio 2.10, 95% confidence interval 1.02-4.35; P = 0.045). CONCLUSIONS: Immunocompromised patients treated with ECMO support for severe acute respiratory failure had poorer short- and long-term prognoses than did immunocompetent patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Na SJ, Park SH, Hong SB, et al. Clinical outcomes of immunocompromised patients on extracorporeal membrane oxygenation support for severe acute respiratory failure. Eur J Cardiothorac Surg. 2020. PMID: 31625551. doi:10.1093/ejcts/ezz276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。